{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:55:03Z","timestamp":1783112103121,"version":"3.54.6"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Type 2 diabetes mellitus (T2D) represents a major public health challenge with significant effects on morbidity and mortality. Clinical guidelines provide treatment recommendations, but there is limited understanding of patients\u2019 preferences. This study aimed to elicit preferences for second-line drug treatments for T2D.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>A Discrete Choice Experiment with a partial-profile design was conducted from August to November 2023, involving German patients with experience in either monotherapy or second-line drug treatment. Participants completed 12 choice tasks, each presenting three alternatives described by attributes: risk of myocardial infarction, risk of stroke, risk of nerve damage, risk of nausea, risk of severe hypoglycemia, weight change, type and frequency of intake, and schedule of intake. Statistical analyses employed the Conditional Logit and Random Parameter Logit models to assess main effects and heterogeneity.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The study encompassed 583 adult individuals with T2D, evenly divided between the two populations. Key factors influencing choice decisions included risk of nausea, risk of nerve damage, and weight change, with weekly type and frequency of intake risk of myocardial infarction followed. Less impactful but still relevant were risks of stroke, and severe hypoglycemia, while the intake schedule was least significant. Analysis of BMI categories revealed distinct preferences, particularly in weight change, with significant heterogeneity observed among respondents.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study highlights the importance of incorporating patient preferences into clinical decision-making. By quantifying preferences for second-line drug treatments, the study underscores the need for low-risk options that also consider weight change and intake conditions, aligning with the German National Health Care Guideline for T2D objectives for shared decision-making and treatment adherence. Recognizing individual sensitivities to risks and benefits is crucial for tailoring effective T2D treatment strategies. The study bridges clinical findings with patient perspectives, offering valuable insights into clinical practice, consideration for HTA processes, and design of clinical studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0329743","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:27:39Z","timestamp":1757957259000},"page":"e0329743","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of patients preferences in type 2 diabetes mellitus second-line drug treatment: A discrete choice experiment"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9306-9020","authenticated-orcid":true,"given":"Ann-Kathrin","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Mathey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"M\u00fchlbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"1","key":"pone.0329743.ref001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes \u2014 global burden of disease and forecasted trends","volume":"10","author":"MAB Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"pone.0329743.ref002","first-page":"510","volume-title":"Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes: Gemeinsam getragen von RKI und DESTATIS. 1. Auflage ed. Beitr\u00e4ge zur Gesundheitsberichterstattung des Bundes","author":"A-C Sa\u00df","year":"2015"},{"issue":"11","key":"pone.0329743.ref003","first-page":"177","article-title":"The prevalence and incidence of diabetes in Germany: an analysis of statutory health insurance data on 65 million individuals from the years 2009 and 2010","volume":"113","author":"T Tamayo","year":"2016","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"5","key":"pone.0329743.ref004","first-page":"1","article-title":"Classification, pathophysiology, diagnosis and management of diabetes mellitus","volume":"6","author":"HW Baynes","year":"2015","journal-title":"J Diabetes Metab"},{"issue":"6","key":"pone.0329743.ref005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/2040622314548679","article-title":"Early onset type 2 diabetes: risk factors, clinical impact and management","volume":"5","author":"E Wilmot","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"pone.0329743.ref006","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jama.292.8.978","article-title":"Sugar-sweetened soft drinks, obesity, and type 2 diabetes","volume":"292","author":"CM Apovian","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"pone.0329743.ref007","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","article-title":"A systematic review of adherence with medications for diabetes","volume":"27","author":"JA Cramer","year":"2004","journal-title":"Diabetes Care"},{"issue":"03","key":"pone.0329743.ref008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/a-0868-7758","article-title":"Motivation und diabetes \u2013 Zeit f\u00fcr einen Paradigmenwechsel? \u2013 Ein Positionspapier \u2013","volume":"14","author":"F Petrak","year":"2019","journal-title":"Diabetol Stoffwechs"},{"key":"pone.0329743.ref009","article-title":"AHRQ comparative effectiveness reviews.","volume-title":"Diabetes medications for adults with type 2 diabetes: an update","author":"S Bolen","year":"2016"},{"key":"pone.0329743.ref010","unstructured":"Nationale Versorgungsleitlinie, et al. Partizipative Entscheidungsfindung, Diagnostik und medikament\u00f6se Therapie bei Typ-2-Diabetes."},{"issue":"12","key":"pone.0329743.ref011","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"MJ Davies","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"pone.0329743.ref012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"JB Buse","year":"2020","journal-title":"Diabetologia"},{"key":"pone.0329743.ref013","unstructured":"Bolen S, et al. Diabetes medications for adults with type 2 diabetes: an update. 2016."},{"issue":"4","key":"pone.0329743.ref014","article-title":"Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus","volume":"4","author":"KS Madsen","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"pone.0329743.ref015","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJMoa2200433","article-title":"Glycemia reduction in type 2 diabetes - glycemic outcomes","volume":"387","author":"DM Nathan","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0329743.ref016","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"L He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"pone.0329743.ref017","doi-asserted-by":"crossref","first-page":"645566","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"MA Nauck","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"pone.0329743.ref018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10198-021-01264-6","article-title":"Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment","volume":"22","author":"AC M\u00fchlbacher","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"4","key":"pone.0329743.ref019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40271-017-0253-9","article-title":"Health preference research: an overview","volume":"10","author":"BM Craig","year":"2017","journal-title":"Patient"},{"issue":"3","key":"pone.0329743.ref020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40258-016-0232-7","article-title":"Choice experiments to quantify preferences for health and healthcare: state of the practice","volume":"14","author":"A M\u00fchlbacher","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"pone.0329743.ref021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1037\/h0070288","article-title":"A law of comparative judgment","volume":"34","author":"LL Thurstone","year":"1927","journal-title":"Psychol Rev"},{"key":"pone.0329743.ref022","first-page":"105","article-title":"Conditional logit analysis of qualitative choice behavior.","volume-title":"Zarembka","author":"D McFadden","year":"1974"},{"issue":"6","key":"pone.0329743.ref023","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/1475-6773.01116","article-title":"Measuring what people value: a comparison of \u201cattitude\u201d and \u201cpreference\u201d surveys","volume":"37","author":"KA Phillips","year":"2002","journal-title":"Health Serv Res"},{"issue":"7248","key":"pone.0329743.ref024","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"M Ryan","year":"2000","journal-title":"BMJ"},{"key":"pone.0329743.ref025","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511753831","volume-title":"Stated choice methods: analysis and applications","author":"J Louviere","year":"2000"},{"issue":"2","key":"pone.0329743.ref026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","article-title":"Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment","volume":"18","author":"AC M\u00fchlbacher","year":"2017","journal-title":"Eur J Health Econ"},{"key":"pone.0329743.ref027","volume-title":"Discrete choice analysis: theory and application to travel demand, Vol. 2","author":"M Ben-Akiva","year":"1985"},{"key":"pone.0329743.ref028","volume-title":"Discrete choice analysis: theory and application to travel demand","author":"ME Ben-Akiva","year":"1985"},{"key":"pone.0329743.ref029","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511610356","volume-title":"Applied choice analysis: a primer","author":"DA Hensher","year":"2005"},{"issue":"4","key":"pone.0329743.ref030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/1312067-200801040-00003","article-title":"Why not ask?: Measuring patient preferences for healthcare decision making","volume":"1","author":"FR Johnson","year":"2008","journal-title":"Patient"},{"issue":"8","key":"pone.0329743.ref031","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","article-title":"Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide","volume":"26","author":"E Lancsar","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"pone.0329743.ref032","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hec.1697","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"21","author":"EW de Bekker-Grob","year":"2012","journal-title":"Health Econ"},{"issue":"9","key":"pone.0329743.ref033","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"MD Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"pone.0329743.ref034","volume-title":"Conjoint analysis use in health studies \u2013 a checklist: a report of the ISPOR conjoint analysis in health good research practices task force","author":"J Bridges","year":"2011"},{"issue":"1","key":"pone.0329743.ref035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"F Reed Johnson","year":"2013","journal-title":"Value Health"},{"issue":"2","key":"pone.0329743.ref036","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","article-title":"A roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR task force","volume":"26","author":"JFP Bridges","year":"2023","journal-title":"Value Health"},{"issue":"8","key":"pone.0329743.ref037","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jval.2022.01.015","article-title":"The sensitivity and specificity of repeated and dominant choice tasks in discrete choice experiments","volume":"25","author":"MF Jonker","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"pone.0329743.ref038","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2501\/S1470785310201673","article-title":"Using partial profile choice experiments to handle large numbers of attributes","volume":"52","author":"K Chrzan","year":"2010","journal-title":"Int J Market Res"},{"issue":"3","key":"pone.0329743.ref039","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hec.3846","article-title":"Attribute level overlap (and color coding) can reduce task complexity, improve choice consistency, and decrease the dropout rate in discrete choice experiments","volume":"28","author":"MF Jonker","year":"2019","journal-title":"Health Econ"},{"key":"pone.0329743.ref040","volume-title":"Lighthouse studio manual","author":"Sawtooth Software","year":"2022"},{"issue":"3","key":"pone.0329743.ref041","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00133443","article-title":"The structure of random utility models","volume":"8","author":"CF Manski","year":"1977","journal-title":"Theor Decis"},{"issue":"8","key":"pone.0329743.ref042","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","article-title":"Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide","volume":"26","author":"E Lancsar","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"pone.0329743.ref043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4020-5753-3_1","article-title":"Discrete choice experiments in a nutshell.","volume-title":"Using discrete choice experiments to value health and health care","author":"M Ryan","year":"2008"},{"key":"pone.0329743.ref044","unstructured":"McFadden D. Conditional logit analysis of qualitative choice behavior. 1973."},{"issue":"7","key":"pone.0329743.ref045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","article-title":"Discrete choice experiments: a guide to model specification, estimation and software","volume":"35","author":"E Lancsar","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"pone.0329743.ref046","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jhealeco.2007.11.006","article-title":"Modelling heterogeneity in patients\u2019 preferences for the attributes of a general practitioner appointment","volume":"27","author":"AR Hole","year":"2008","journal-title":"J Health Econ"},{"issue":"4","key":"pone.0329743.ref047","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"AB Hauber","year":"2016","journal-title":"Value Health"},{"issue":"10","key":"pone.0329743.ref048","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/hec.984","article-title":"Effects coding in discrete choice experiments","volume":"14","author":"M Bech","year":"2005","journal-title":"Health Econ"},{"key":"pone.0329743.ref049","volume-title":"Stata statistical software: release 17","author":"StataCorp","year":"2022"},{"key":"pone.0329743.ref050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00508-018-1418-9","article-title":"\u201cDiabesity\u201d-obesity and type 2 diabetes (Update 2019)","volume":"131","author":"H Toplak","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"pone.0329743.ref051","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","article-title":"Body weight considerations in the management of type 2 diabetes","volume":"36","author":"CM Apovian","year":"2019","journal-title":"Adv Ther"},{"issue":"1","key":"pone.0329743.ref052","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","article-title":"Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment","volume":"18","author":"S Fifer","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"pone.0329743.ref053","first-page":"1443","article-title":"Patients\u2019 and physicians\u2019 preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment","volume":"9","author":"C Morillas","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"pone.0329743.ref054","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s13300-017-0326-8","article-title":"Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment Survey","volume":"8","author":"C Mansfield","year":"2017","journal-title":"Diabetes Ther"},{"issue":"7","key":"pone.0329743.ref055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jval.2020.01.023","article-title":"Patient preferences for medications in managing type 2 diabetes mellitus: a discrete choice experiment","volume":"23","author":"S Ozdemir","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"pone.0329743.ref056","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13300-019-0591-9","article-title":"Patient preferences for GLP-1 receptor agonist treatment of type 2 diabetes mellitus in japan: a discrete choice experiment","volume":"10","author":"A Brooks","year":"2019","journal-title":"Diabetes Ther"},{"key":"pone.0329743.ref057","article-title":"Patient preferences in pulmonary arterial hypertension, a latent class analysis to identify preference heterogeneity","author":"A M\u00fchlbacher","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"pone.0329743.ref058","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40271-023-00656-5","article-title":"Preferences for monitoring comprehensive heart failure care: a latent class analysis","volume":"17","author":"AC M\u00fchlbacher","year":"2024","journal-title":"Patient"},{"key":"pone.0329743.ref059","article-title":"The effect of level overlap and color coding on attribute non-attendance in discrete choice experiments","author":"MF Jonker","year":"2017","journal-title":"Value Health"},{"key":"pone.0329743.ref060","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.endmts.2020.100053","article-title":"Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative \u201cdiabetes and nerves\u201d","volume":"1","author":"A Pfannkuche","year":"2020","journal-title":"Endocr Metab Sci"},{"key":"pone.0329743.ref061","article-title":"Clinical practice guideline: shared decision making, diagnostic evaluation, and pharmacotherapy in type 2 diabetes. National Disease Management Guideline","author":"C Brockamp","year":"2023","journal-title":"Dtsch Arztebl Int"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:27:49Z","timestamp":1757957269000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329743"}},"subtitle":[],"editor":[{"given":"Hidetaka","family":"Hamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329743","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}